
    
      The only effective (to some extend drug) in short bowel syndrome is Glucacone-like peptide 4.
      Its price is, however, to high to really change the treatment strategy for intestinal
      failure. The Dipeptidyl peptidase-4 inhibitor, which a drug which is commonly used in the
      treatment of diabetes mellitus type II, should increase the concentration of glucagone-like
      peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of
      the intestine.
    
  